StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
In April, Revolution shares rocketed 54% after the company announced dazzling data from its Phase III RASolute 302 trial (NCT06625320) evaluating Rasonque in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. In the overall intent-to-treat population of the Phase III RASolute 302 trial (NCT06625320), daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated for standard-of-care chemotherapy.
